Genprex, Inc.
Clinical trials sponsored by Genprex, Inc., explained in plain language.
-
Gene therapy duo takes on tough lung cancer
Disease control Recruiting nowThis study tests a new gene therapy (quaratusugene ozeplasmid) combined with an immunotherapy drug (atezolizumab) as maintenance treatment for people with extensive-stage small cell lung cancer. The goal is to see if this combination can keep the cancer from growing longer than s…
Phase: PHASE1, PHASE2 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
Gene therapy combo offers new hope for Drug-Resistant lung cancer
Disease control Recruiting nowThis study tests a new gene therapy (quaratusugene ozeplasmid) added to the standard drug osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. The gene therapy aims to restore a tumor-suppressing gene. About…
Phase: PHASE1, PHASE2 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated May 17, 2026 04:16 UTC